Carregant...
Nivolumab and immune‐mediated colitis
Nivolumab is associated with a number of immune‐regulated adverse events, including immune‐mediated colitis and may present following the discontinuation of treatment. Current guidance suggests lower doses of methylprednisolone; however, we described faster resolution of the patient's symptoms...
Guardat en:
| Publicat a: | Clin Case Rep |
|---|---|
| Autors principals: | , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
John Wiley and Sons Inc.
2019
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6452469/ https://ncbi.nlm.nih.gov/pubmed/30997054 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ccr3.2027 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|